Invesco Pharmaceuticals ETF

PJP

Market cap $341M

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

U.S. President Donald Trump will ‌announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his ​administration's pricing deal, on Monday, a White ​House official said.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.

When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

On Thursday, news broke that the US will likely start levying a 100% tariff on branded pharmaceutical imports. The specifics remain unclear, but the levy is expected to be relatively narrow in scope, since many exemptions have already been negotiated.

Britain said on Thursday it ​had agreed the ‌full text of a U.S.-UK pharmaceutical partnership, ​setting out terms ​under which British-made medicines ⁠would enter the ​United States tariff-free.

Europe's pharmaceutical industry needs to make sure it doesn't become yesterday's news. Its biopharmaceutical innovation capacity has been gradually declining for decades, and the rapid ascent of China and President Trump's policies risk accelerating that decay.